Valuation : Mymetics Corporation

Market Cap 4L 4L 4L 3L 6L 4.19Cr 6L 41.75L 16.32L 2.11Cr 16.47L 16.12L 6.99Cr P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 7.21Cr 6.19Cr 5.8Cr 5.31Cr 10Cr 688.83Cr 10Cr 69Cr 27Cr 347.16Cr 27Cr 26Cr 1.15TCr EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
1 day+45.45%
1 week+10,66,566.67%
Current month+10,66,566.67%
1 month+10,66,566.67%
3 months+10,66,566.67%
6 months+10,66,566.67%
Current year+10,66,566.67%
Current year 0
Extreme 0.0003
3.2
1 year 0
Extreme 0.0003
3.2
3 years 0
Extreme 0.0003
5.6
5 years 0
Extreme 0.0003
230
10 years 0
Extreme 0.0003
380
Manager TitleAgeSince
Chief Executive Officer 58 19/11/2012
Change 5-day change 1-year change 3-year change Capi.($)
+45.45%+10,66,566.67%+10,66,566.67%-28.89% 45
+3.31%-3.70%+61.03%+103.64% 7.06TCr
-0.55%+0.04%+49.75%+92.16% 6.61TCr
-1.03%+0.46%+8.14%-5.28% 2.8TCr
-2.41%-2.95%-9.77%+455.82% 2.65TCr
+0.30%-0.69%+63.18%+11.93% 2.64TCr
+1.02%+6.43%+269.42%+420.34% 2.04TCr
+0.25%+1.16%+34.95%-17.26% 2.02TCr
-1.91%-4.37%+13.33%+531.29% 1.6TCr
-1.50%+2.92%+43.50%+151.30% 1.37TCr
Average +4.29%+0.89%+1,06,710.02%+171.50% 2.88TCr
Weighted average by Cap. +0.30%+0.65%+56.44%+154.42%

Financials

2021 2022
Net sales 4L 4L 3L 3L 6L 4.11Cr 6L 40.92L 16L 2.07Cr 16.14L 15.8L 6.85Cr 10.28L 9L 8L 8L 14.25L 9.82Cr 14.29L 97.83L 38.24L 4.95Cr 38.6L 37.76L 16Cr
Net income -47.3L -40.6L -38.01L -34.81L -65.57L -45Cr -65.76L -4.5Cr -1.76Cr -23Cr -1.78Cr -1.74Cr -75Cr -48.05L -41.25L -38.62L -35.36L -66.61L -46Cr -66.8L -4.57Cr -1.79Cr -23Cr -1.8Cr -1.77Cr -77Cr
Net Debt 6.71Cr 5.76Cr 5.39Cr 4.94Cr 9.3Cr 640.86Cr 9.33Cr 64Cr 25Cr 322.99Cr 25Cr 25Cr 1.07TCr 7.17Cr 6.15Cr 5.76Cr 5.28Cr 9.94Cr 684.64Cr 9.97Cr 68Cr 27Cr 345.05Cr 27Cr 26Cr 1.14TCr
Logo Mymetics Corporation
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
-
  1. Stock Market
  2. Stocks
  3. MYMX Stock